All In Biotech

Drug Trial Radar · NCT07024212

Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of DR10624 Injection in Subjects at High Risk of Liver Fibrosis With Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction and Alcohol Associated Steatotic Liver Disease

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Jun 18, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts. The primary objective of Part 1 is to assess the preliminary efficacy of DR10624 Injection in MASLD subjects at high risk of liver fibrosis. The secondary objectives are to assess the safety and tolerability, PK profiles, and immunogenicity of DR10624 Injection in these subjects. The exploratory objectives are to assess the efficacy of DR10624 Injection in these subjects using LSM assessed by MRE, and its impact on Lp(a) and body composition.The primary objective of Part 2 is to assess the safety and tolerability of DR10624 Injection in MetALD subjects at high risk of liver fibrosis. This clinical trial is currently only conducting Part 1 of the study.

Conditions

  • MASLD

Interventions

  • DR10624 InjectionDrug

    Drug: DR10624 injection

  • PlaceboDrug

    Drug: Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes of LFCTime frame: From baseline to Week 12

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, China

  • Nanjing Gulou Hospital

    Nanjing, China

  • The Affiliated Hospital of Hangzhou Normal University

    Hangzhou, Zhejiang, China

  • Prince of Wales Hospital, The Chinese University of Hong Kong

    Hong Kong, Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.